# **Resource Summary Report**

Generated by <u>RRID</u> on Apr 8, 2025

# **KeytoLead**

RRID:SCR\_004084 Type: Tool

**Proper Citation** 

KeytoLead (RRID:SCR\_004084)

#### **Resource Information**

URL: http://www.keytolead.se/

Proper Citation: KeytoLead (RRID:SCR\_004084)

Description: THIS RESOURCE IS NO LONGER IN SERVICE, documented May 10, 2017. A pilot effort that has developed a centralized, web-based biospecimen locator that presents biospecimens collected and stored at participating Arizona hospitals and biospecimen banks. which are available for acquisition and use by researchers. Researchers may use this site to browse, search and request biospecimens to use in qualified studies. The development of the ABL was guided by the Arizona Biospecimen Consortium (ABC), a consortium of hospitals and medical centers in the Phoenix area, and is now being piloted by this Consortium under the direction of ABRC. You may browse by type (cells, fluid, molecular, tissue) or disease. Common data elements decided by the ABC Standards Committee, based on data elements on the National Cancer Institute"s (NCI"s) Common Biorepository Model (CBM), are displayed. These describe the minimum set of data elements that the NCI determined were most important for a researcher to see about a biospecimen. The ABL currently does not display information on whether or not clinical data is available to accompany the biospecimens. However, a requester has the ability to solicit clinical data in the request. Once a request is approved, the biospecimen provider will contact the requester to discuss the request (and the requester"s questions) before finalizing the invoice and shipment. The ABL is available to the public to browse. In order to request biospecimens from the ABL, the researcher will be required to submit the requested required information. Upon submission of the information, shipment of the requested biospecimen(s) will be dependent on the scientific and institutional review approval. Account required. Registration is open to everyone.. Documented on August 12, 2021. Commercial organization with expertise in lead generation, such as compound selection, iterative screens, fragment based lead generation (FBLG), HTS evaluation (clustering, scoring and actives selection), development of clusters into lead series (expansion via compound libraries, scaffold hopping and multi-parameter optimization), management of secondary screens (physical properties,

ADMET), project management and presentation for customers or scientific committees. Synthetic organic chemistry is an important area of lead generation which is why both single compound synthesis and compound library synthesis are integrated. The scientists are skilled in predictive models including target modelling, virtual screening, high quality compound library design, compound triage and design, compound synthesis (including parallel synthesis) and automated purification. KeytoLead management team also has experience in leadership, line management, international collaborations, intellectual property and continuous improvement.

Abbreviations: KeytoLead

Synonyms: KeytoLead AB

Resource Type: commercial organization

Keywords: drug discovery, lead generation

Funding:

Availability: THIS RESOURCE IS NO LONGER IN SERVICE

Resource Name: KeytoLead

Resource ID: SCR\_004084

Alternate IDs: nlx\_158542

Record Creation Time: 20220129T080222+0000

Record Last Update: 20250214T183049+0000

## **Ratings and Alerts**

No rating or validation information has been found for KeytoLead.

No alerts have been found for KeytoLead.

## Data and Source Information

Source: <u>SciCrunch Registry</u>

#### **Usage and Citation Metrics**

We found 1 mentions in open access literature.

Listed below are recent publications. The full list is available at <u>RRID</u>.

Persson CU, et al. (2020) ARNT-dependent HIF-2 transcriptional activity is not sufficient to

regulate downstream target genes in neuroblastoma. Experimental cell research, 388(2), 111845.